Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

• Main Authors: Ratnakar Reddy Kuchukulla (Author), Injeoung Hwang (Author), Sang Won Park (Author), Sojeong Moon (Author), Suhn Hyung Kim (Author), Sumin Kim (Author), Hwan Won Chung (Author), Mi-Jung Ji (Author), Hyun-Mee Park (Author), Gu Kong (Author), Wooyoung Hur (Author)
• Format: Book
• Published: MDPI AG, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

HER2-positive (HER2+) breast cancer is defined by <i>HER2</i> oncogene amplification on chromosome 17q12 and accounts for 15-20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. Ho...